AI assistant
SCI Interim / Quarterly Report 2020
52383_rns_2020-12-18_a9e9f3fd-f19a-4b99-88cc-ea27d4d86cad.pdf
Interim / Quarterly Report
Open in viewerOpens in your device viewer
員工數Employee:278 設立日期:中華民國七十六年九月十八日 Date of establishment: Sep. 18, 1987 資本額Capital:新台幣795佰萬元(NTD 795mn) 營業項目Business: 原料藥API(73.71%) 中間體Intermediate(21.56%) 特用化學品 Custom-made chemicals(4.73%)
公司概況Outline
| Jan~Nov, 2020 Sales | Y2019 Sales | |||
|---|---|---|---|---|
| 歐 洲Europe |
52.61% | 53.96% | ||
| 美 洲America |
18.34% | 14.49% | ||
| 洲Asia 亞 |
17.08% | 21.33% | ||
| 國 內Taiwan |
7.98% | 9.39% | ||
| 其 他 others |
3.99% | 0.83% | ||
| 合 計Total |
100.00% | 100.00% | ||
Unit: K NTD
| 2020.Q1-Q3 | 2020, Oct | |
|---|---|---|
| 營收Sales | 2,191,085 | 205,215 |
| 營業成本COGS | (1,142,766) | (121,911) |
| 毛利Gross Profit | 1,048,319 | 83,304 |
| 毛利率 GP Ratio | 47.8% | 40.6% |
| 營業費用Operating Expenses | (228,103) | (17,411) |
| 營業利益Operating Income | 820,216 | 65,893 |
| 營業外損益Non-Operating In/Ex | (19,158) | (6,237) |
| 稅前淨利 Net Profit before Tax | 801,058 | 59,656 |
| 所得稅Income Tax | (162,141) | - |
| 本期淨利Net Profit after Tax | 638,917 | 59,656 |
產品組合-Products
| Y2017 | % | Y2018 | % | Y2019 | % | |
|---|---|---|---|---|---|---|
| S-MMAA / Dulo | 13.14 | HOCLQ Sulfate | 22.29 | VA Series | 22.91 | |
| VA Series | 12.48 | VA Series | 16.70 | S-MMAA /Dulo | 15.55 | |
| HOCLQ Sulfate | 12.47 | S-MMAA / Dulo | 12.57 | PGA | 12.45 | |
| LPF.Na | 9.41 | PGA | 9.64 | HOCLQ | 10.32 | |
| PGA | 9.22 | Pent-2 / PEB.Na | 6.68 | Pent-2 / PEB.Na | 6.12 | |
| Pent-2 / PEB.Na | 8.69 | PMDOL / Olivetol | 5.80 | PMDOL+Olivetol | 5.84 | |
| 5-HMT / 5-Wing 6.26 |
5-HMT / 5-Wing 2.95 |
LPF.Na | 4.07 | |||
| Total | 71.67 | Total | 76.63 | Total | 77.26 |
產品組合-Products
| Product | % | Jan~Nov, 2020 Sales (NT\$) |
|---|---|---|
| VA series | 26.25 | 685,402,978 |
| HOCLQ Sulfate | 21.26 | 554,979,744 |
| S-MMAA / Dulo.Hcl | 14.06 | 366,970,242 |
| PGA | 11.05 | 286,092,275 |
| Pent-2 / PEB.Na | 6.57 | 157,389,177 |
| BZA | 3.55 | 92,752,547 |
| 5-HTM / 5-Wing | 3.10 | 81,056,623 |
| PF.Hcl | 2.18 | 55,931,255 |
VA Series:
Valproic Acid, Divalproex Sodium, Sodium Valproate
適應症 Application: 癲癇(seizure)、躁鬱症(bipolar disorder)、 偏頭痛(migraine headaches)
S-MMAA / Duloxetine HCl
適應症 Application: 重鬱症(major depressive disorder)、廣泛性焦慮症 (generalized anxiety disorder) 、糖尿病週邊神經痛 (diabetic neuropathy) 、纖維肌痛(Fibromyalgia)、 慢性腰痛(日本地區) lower back pain (only in Japan)
Pyrogallolaldehyde ( PGA)
Benserazide 治療帕金森氏症之中間體 Intermediate for Parkinson's Disease
Hydroxychloroquine sulfate
適應症 Application: 類風濕性關節炎(rheumatoid arthritis) 、瘧疾 (malaria)、 慢性多形性日光疹、慢性圓板狀紅斑症 (discoid and systemic lupus erythematosus)
Pent-2 / Pentobarbital Sodium
鎮定安眠用中間體及原料藥 Intermediate and API for calmative
Menthadienol, Olivetol, Ethyl Olivetolate
- 為Dronabinol (THC 四氫大麻酚)及Cannabidiol (CBD大麻二酚) 之關鍵中間體 The key intermediates for Dronabinol (THC) and Cannabidiol (CBD)
- THC 適應症 Applications:
- 化療引起的噁心、嘔吐 Nausea and vomiting due to chemotherapy
- 愛滋病引起之厭食症 anorexia due to AIDS
- CBD 適應症 Applications:
- Epidiolex:兒童罕見癲癇以及多發性硬化症 For seizures in patients aged 2 years and older, and Multiple Sclerosis.
CBD (Cannabidiol)
- CBD之應用廣泛:從癲癇、巴金森氏症、阿茲海默症,到關節炎 、躁鬱 、焦慮、失眠、止痛、抗發炎等。
- 市場預估:
- 美國市場:2020年預估值為美金290億 ? 全球大麻與其衍生物之應用(醫藥、保健、美容等):美金兩千億?
旭富 CBD (Cannabidiol)
- 製程放大成功,已取得台灣外銷專用許可證及美國藥證 (US DMF)
- 2020年初完成確效,申請台灣製藥許可證中
- 開始業務開發與小量試銷
CBD (Cannabidiol)
- Wide range of medical benefits, from epilepsy, Parkinson's and Alzheimer's disease, bipolar disorder, anxiety, pain, inflammation, to arthritis, insomnia, etc.
- Market estimations:
US market: US\$ 29 billions in 2020?
Total Cannabis Opportunity (pharmaceutical, nutraceutical, beauty, etc.): ~ US\$ 200 billions ??
CBD (Cannabidiol) by SCI
- Scaled-up successfully and obtained TFDA export license and US DMF
- Completed validation in early 2020, applying domestic license with TFDA.
- BD started, qualification / trials on-going.
| $\left( \mathrm{I}\right)$ | API | DMF (USA) CEP (EDQM) | MF (Japan) | DMF (Canada) | CGMP certified (TFDA) |
China DMF | |
|---|---|---|---|---|---|---|---|
| $\mathbf{1}$ | Articaine Hydrochloride | 2014 | 2014 | 2013 | |||
| $\overline{2}$ | Allopurino1 | 2011 | 2003 | 2004 | |||
| $\overline{3}$ | Atomoxetine Hydrochloride | 2018 | 2018 | 2016 | |||
| $\overline{4}$ | Bisoprolol Fumarate | 2006 | |||||
| 5 | Brinzolamide | 2015 | 2017 | 2015 | |||
| 6 | Clindamycin Palmitate HCl | 2011 | |||||
| $\overline{7}$ | Cyclophosphamide | 2014 | |||||
| 8 | Divalproex Sodium | 2005 | 2010 | 2005 | 2010 | ||
| 9 | Duloxetine Hydrochloride | 2011 | 2014 | 2017 | 2016 | 2012 | 2013 |
| 10 | Hydroxychloroquine Sulfate | 2014 | 2019 | 2014 | 2014 | 2020 | |
| 11 | Loxoprofen Sodium Hydrate | 2011 | 2012 | ||||
| 12 | Methylphenidate HCl | 2014 | 2011 | ||||
| 13 | Pentobarbital Sodium | 2011 | 2009 | ||||
| 14 | Probucol | 2004 | 2017 | 2015 | 2015 | ||
| 15 | Propafenone Hydrochloride | 2010 | 2012 | 2012 | 2012 | 2010 | 2018 |
| 16 | Sodium Valproate | 2019 | 2006 | 2017 | 2004 | 2014 | |
| 17 | Thiopental | 2012 | |||||
| 18 | Valproic Acid | 2003 | 2004 | 2008 | 2008 | 2003 | 2019 |
| 19 | Cannabidiol (CBD) | 2020 | |||||
| (II) | API intermediate | DMF (USA) CEP (EDQM) | MF (Japan) | DMF (Canada) | CGMP certified (TFDA) |
China DMF | |
| $\mathbf{1}$ | Menthadienol (PMDOL) | 2019 | |||||
| $\overline{2}$ | Oliveto1 | 2019 | |||||
| $\overline{3}$ | Ethyl Olivetolate | 2019 |
